301 - 312 of 7723 results
0.5 CME CREDIT

Polypharmacy, defined as the use of multiple drugs or more than are medically necessary, is a growing concern for older adults. With older adults living longer and experiencing multiple chronic comorbidities, medication regimens are becoming increasingly complex and lengthy. It is not unusual to see patients taking 10 or more medications. Unfortunately, polypharmacy has been associated with an increased risk of adverse drug events (ADEs), drug-interactions, medication non-adherence, reduced functional capacity and multiple geriatric syndromes. This lecture will present real-world cases of polypharmacy and review the concepts of de-prescribing, what medications are no longer considered helpful to older adults, and how to safely reduce polypharmacy in real-world settings among patients.


Early Recognition of Interstitial Lung Disease

Industry Webcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit

During this virtual Industry Theater presentation, an expert pulmonologist who specializes in the field of interstitial lung diseases (ILDs) will discuss the complexity of ILD recognition, with a focus on diagnostic criteria and the importance of collaborating with specialists for a timely diagnosis of ILDs


REGENERON AND SANOFI GENZYME

Learn More About the Impact and Management of Moderate-to-Severe Atopic Dermatitis in Appropriate Patients ©2020 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. 12/2020 DER.20.08.0013


Jardiance<sup>®</sup> (empagliflozin) tablets

To learn more about JARDIANCE safety and efficacy data as well as information about initiating JARDIANCE in your patients, please access the below link.                                                                                                                                                                                    www.JARDIANCELectureSeries.com                                                                                                                                                                               Copyright © 2020 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (11/20) EM-US-101640


Early Recognition of Interstitial Lung Disease

Industry Webcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit

During this virtual Industry Theater presentation, an expert pulmonologist who specializes in the field of interstitial lung diseases (ILDs) will discuss the complexity of ILD recognition, with a focus on diagnostic criteria and the importance of collaborating with specialists for a timely diagnosis of ILDs


computer drawing of a heart

Hospitalization: An Opportunity to Optimize Care for Patients with Heart Failure

Industry Webcast Sponsored by Novartis; Not for CME/CE Credit


Man holding his back

Recognizing IBP (inflammatory back pain) vs MBP (mechanical back pain)

An Adaptive Learning Experience Sponsored by Novartis Pharmaceutical Corporation; Not for CME/CE Credit

Axial spondyloarthritis (axSpA) is a chronic and debilitating inflammatory disease primarily affecting the spine and sacroiliac joints. In the United States alone, it is estimated to take 14 years to receive appropriate diagnosis as it's hallmark symptom, inflammatory back pain, can go unnoticed or be misdiagnosed. Due to the challenges in recognizing axSpA, patients are often referred to various healthcare providers in the journey to diagnosis. There is a significant need to increase the proper diagnosis of axSpA among healthcare professionals, especially those that are seeing patients experiencing back pain. Early identification and timely referral to rheumatologists can help mitigate the progressive structural damage and significant patient burden in axSpA patients.


Management of Chronic Obstructive Pulmonary Disease (COPD): Inhaler Use and Selection

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.; Not for CME/CE Credit


Early Recognition of axSpA in Primary Care Chapter 3: Disease burden in axSpA patients

Industry Webcast Sponsored by Novartis Pharmaceutical Corporation, LLC; Not for CME/CE Credit

View this presentation to learn more about the important role of primary care providers in the early recognition of axSpA. This presentation is the third chapter of a series of videos exploring axSpA. Join us for a live webinar with Dr. Jain on October 27 at 12:40 PM ET.


• Examine the medical burden of influenza and its economic impact in adults 50+ years of age • Explore how influenza can exacerbate chronic health conditions and lead to adverse outcomes • Review clinical evidence of 2 influenza vaccines that were compared to standard-dose influenza vaccines in older adults


Strategies for Effective Pain Management

2.00 CME/MOC
3.10 AANP | 2.08 Pharmacology